oncept il-2
boehringer ingelheim vetmedica gmbh - virus vcp1338 - imunostimulante, antineoplazice si imunomodulatoare, imunostimulatoare, - pisici - imunoterapia pentru a fi utilizate în asociere cu chirurgia și radioterapia la pisici cu fibrosarcom (2-5 cm diametru) fără metastaze sau a ganglionilor limfatici, pentru a reduce riscul de recidivă și de a crește timpul până la recădere (recidiva locală sau metastaze).
tiamulin 10% tetoros
tetoros bros s.a., grecia - tiamulin hidrogen fumarat - pulbere hidrosolubilă - antibiotice - păsări, porcine - porcine, găini tratamentul infecţiilor cauzate de microorganisme sensibile la tiamulin.
neomycin 70 tetoros
tetoros bros s.a., grecia - neomicină sulfat - pulbere hidrosolubilă - antibiotice - păsări, porcine - porcine, găini prevenirea (în efectivele în care diagnosticul a fost confirmat) şi tratamentul enteritelor bacteriene cauzate de microorganisme sensibile la neomicină.
esbriet
roche registration gmbh - pirfenidonă - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - imunosupresoare - esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.
frontline combo spot on câini m (10-20 kg)
merial, franța - fipronil - soluţie spot on - cîini
pirfenidone viatris
viatris limited - pirfenidonă - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - imunosupresoare - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).
kalydeco
vertex pharmaceuticals (ireland) limited - ivacaftor - fibroză chistică - alte produse ale sistemului respirator - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 și 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 și 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.
pazopanib adalvo 200 mg
alvogen malta (out-licensing) ltd./amol ltd. - malta - pazopanib - compr. film. - 200mg - inhibitori de protein-kinaza
pyzypi 200 mg
remedica ltd - cipru - pazopanibum - compr. film. - 200mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
pyzypi 400 mg
remedica ltd - cipru - pazopanibum - compr. film. - 400mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza